Literature DB >> 1694039

Regulation of isotype immunoglobulin production by adjuvants in vivo.

E E Karagouni1, L Hadjipetrou-Kourounakis.   

Abstract

Mice were immunized against fluorescein isothiocyanate (FITC)-labelled human gamma globulin (HGG) or dextran sulphate (DXS) in the absence or presence of different adjuvants. The immune response was assayed as the total Ig-secreting cells and FITC-specific plaque-forming cells (PFC) found in various lymphoid organs. The adjuvants influenced the isotype of antibodies produced to the same antigenic determinant. The PFC of different IgG subclasses were favoured by different adjuvants. The IgG3 isotype was produced mainly after immunization with either antigen and lipopolysaccharide (LPS) or Li salt as adjuvant; IgG1 was produced with incomplete Freund's adjuvant (IFA), complete Freund's adjuvant (CFA), alum, poly I:C, Quil A, Be salt, and poly A:U. Some of the above adjuvants (Be salt and poly A:U) favoured the production of IgG2b, and others (CFA, alum, Quil A, and poly I:C) favoured the IgG2a isotype besides the main isotype. Attempts were made to correlate the activation by the various adjuvants of certain TH subtypes with the isotypes produced.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694039     DOI: 10.1111/j.1365-3083.1990.tb02826.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  12 in total

1.  Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Differential stimulation of immune function by respiratory and contact chemical allergens.

Authors:  R J Dearman; I Kimber
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

Review 3.  Old and new adjuvants.

Authors:  Amy S McKee; Philippa Marrack
Journal:  Curr Opin Immunol       Date:  2017-07-19       Impact factor: 7.486

4.  Beryllium, an adjuvant that promotes gamma interferon production.

Authors:  J Y Lee; O Atochina; B King; L Taylor; M Elloso; P Scott; M D Rossman
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

5.  Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.

Authors:  G W Anderson; S E Leary; E D Williamson; R W Titball; S L Welkos; P L Worsham; A M Friedlander
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

6.  Increased adjuvant efficacy in stimulation of antibody responses after macrophage elimination in vivo.

Authors:  P P Leenaars; H F Savelkoul; C F Hendriksen; N Van Rooijen; E Claassen
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

7.  Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.

Authors:  I M Fernández; A Snijders; B J Benaissa-Trouw; M Harmsen; H Snippe; C A Kraaijeveld
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

8.  A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.

Authors:  A Snijders; B J Benaissa-Trouw; H J Visser-Vernooy; I Fernandez; H Snippe; C A Kraaijeveld
Journal:  Immunology       Date:  1992-11       Impact factor: 7.397

9.  Immunization with recombinant Sao protein confers protection against Streptococcus suis infection.

Authors:  Yuanyi Li; Marcelo Gottschalk; Miriam Esgleas; Sonia Lacouture; J Daniel Dubreuil; Philip Willson; Josee Harel
Journal:  Clin Vaccine Immunol       Date:  2007-06-13

10.  Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.

Authors:  A F Verheul; J A Van Gaans; E J Wiertz; H Snippe; J Verhoef; J T Poolman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.